Pralmorelin, also known as GHRP-2 (Growth Hormone-Releasing Peptide-2) and KP-102, is a synthetic hexapeptide that acts as a growth hormone secretagogue. The peptide consists of the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ and has the molecular formula C₄₅H₅₅N₉O₆ with an active-moiety molecular weight of approximately 817.98 g/mol.
For pharmaceutical use, Pralmorelin is associated with its hydrochloride salt form, specifically Pralmorelin Dihydrochloride, CAS 158827-34-0, with a molecular weight of approximately 890.90 g/mol. The Japanese JAN database lists Pralmorelin Hydrochloride as the dihydrochloride salt, while Japan's PMDA approved Pralmorelin Hydrochloride (GHRP Kaken 100) as a diagnostic agent for examination of growth-hormone secretory function.
Pralmorelin is a synthetic peptide and agonist of the growth hormone secretagogue receptor (GHSR). It stimulates growth hormone secretion and has been used clinically in Japan as a diagnostic agent for evaluating growth hormone secretory function. PMDA records Pralmorelin Hydrochloride as an approved diagnostic ingredient, while KEGG classifies it as an endocrine-function diagnostic agent.
Unlike conventional small-molecule APIs, Pralmorelin requires peptide-specific quality controls. Identity confirmation may include chromatographic analysis, mass spectrometry and other structural characterization techniques. Peptide purity is commonly evaluated using reversed-phase HPLC, while molecular identity can be confirmed by mass spectrometry.
Pralmorelin is a six-amino-acid synthetic peptide containing both D- and L-configured residues. The active peptide has the condensed sequence H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂. PubChem and FDA GSRS identify Pralmorelin under CAS 158861-67-7, while the dihydrochloride pharmaceutical salt has CAS 158827-34-0.
The hydrochloride form has the composition C₄₅H₅₅N₉O₆·2HCl and molecular weight 890.90 g/mol.
Pralmorelin Hydrochloride has an established diagnostic application in Japan for assessment of growth hormone secretory function. PMDA documentation lists GHRP Kaken 100 for Injection as a diagnostic product containing Pralmorelin Hydrochloride.
Scientific literature also describes GHRP-2 as a potent growth hormone-releasing peptide and identifies Pralmorelin Hydrochloride as its generic pharmaceutical name.
Because Pralmorelin is a peptide API, conventional small-molecule tests such as melting point and residue on ignition are not necessarily the most meaningful universal release criteria. More appropriate controls include peptide identity, chromatographic purity, molecular-mass confirmation, water/moisture, residual solvents and, where relevant, microbial and endotoxin testing.
Commercial peptide analytical references commonly report ≥98% HPLC purity, but these are commercial/research specifications and should not be represented as a pharmacopoeial Pralmorelin release limit.
A pharmaceutical API manufacturing program for Pralmorelin should control peptide synthesis, purification, salt formation, lyophilization and packaging under appropriate quality systems. Batch-specific analytical documentation should establish identity, purity and consistency of the peptide material.
For customers requiring pharmaceutical-grade peptide API documentation, appropriate records may include a Certificate of Analysis, analytical methods, batch results, residual-solvent information, elemental impurity assessment, stability information and other regulatory documentation applicable to the intended market.
Pralmorelin peptide material is generally handled as a lyophilized powder and should be protected from moisture and excessive temperature. Research-grade peptide references commonly recommend refrigerated or frozen, desiccated storage; the exact storage condition for a pharmaceutical API should follow the validated stability program and approved product specification.
Typical documentation can include:
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |